Browse > Article
http://dx.doi.org/10.5483/BMBRep.2019.52.3.048

Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?  

Poondla, Naresh (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Chandrasekaran, Arun Pandian (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Kim, Kye-Seong (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Ramakrishna, Suresh (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Publication Information
BMB Reports / v.52, no.3, 2019 , pp. 181-189 More about this Journal
Abstract
Cancer remains a life-threatening disease and accounts for the major mortality rates worldwide. The practice of using biomarkers for early detection, staging, and customized therapy may increase cancer patients' survival. Deubiquitinating enzymes (DUBs) are a family of proteases that remove ubiquitin tags from proteins of interest undergoing proteasomal degradation. DUBs play several functional roles other than deubiquitination. One of the important roles of DUBs is regulation of tumor progression. Several reports have suggested that the DUB family members were highly-elevated in various cancer cells and tissues in different stages of cancer. These findings suggest that the DUBs could be used as drug targets in cancer therapeutics. In this review, we recapitulate the role of the DUB family members, including ubiquitin-specific protease, otubain protease, and important candidates from other family members. Our aim was to better understand the connection between DUB expression profiles and cancers to allow researchers to design inhibitors or gene therapies to improve diagnosis and prognosis of cancers.
Keywords
Cancer; Deubiquitinating enzymes; Gene therapy; Inhibitors; Otubain protease; Ubiquitin-specific protease;
Citations & Related Records
연도 인용수 순위
  • Reference
1 McFarlane C, McFarlane S, Paul I et al (2013) The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis. Oncotarget 4, 1836-1843   DOI
2 Peng L, Hu Y, Chen D, Jiao S and Sun S (2016) Ubiquitin specific peptidase 21 regulates interleukin-8 expression, stem-cell like property of human renal cell carcinoma. Oncotarget 7, 42007-42016   DOI
3 Kim Y-H, Kim WT, Jeong P et al (2014) Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. J Korean Med Sci 29, 351   DOI
4 Yang M, Liu YD, Wang YY, Liu TB, Ge TT and Lou G (2014) Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumor Biol 35, 929-934   DOI
5 Piao S, Liu Y, Hu J et al (2012) USP22 Is Useful as a Novel Molecular Marker for Predicting Disease Progression and Patient Prognosis of Oral Squamous Cell Carcinoma. PLoS One 7, e42540   DOI
6 Jia M, Guo Y and Lu X (2018) USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma. Cell Physiol Biochem 45, 2044-2053   DOI
7 Wang H, Li YP, Chen JH et al (2013) Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Tumor Biol 34, 1635-1639   DOI
8 Akhavantabasi S, Akman HB, Sapmaz A, Keller J, Petty EM and Erson AE (2010) USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm Genome 21, 388-397   DOI
9 Hu W, Wei H, Li K, Li P, Lin J and Feng R (2017) Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer. Cell Prolif 50, e12343   DOI
10 Baietti MF, Simicek M, Abbasi Asbagh L et al (2016) OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination. EMBO Mol Med 8, 288-303   DOI
11 Stanisic V, Malovannaya A, Qin J, Lonard DM and O'Malley BW (2009) OTU Domain-containing Ubiquitin Aldehyde-binding Protein 1 (OTUB1) Deubiquitinates Estrogen Receptor (ER) ${\alpha}$ and Affects $ER{\alpha}$ Transcriptional Activity. J Biol Chem 284, 16135-16145   DOI
12 Lee JH, Jung SM, Yang KM et al (2017) A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1. Nat Cell Biol 19, 1260-1273   DOI
13 Guo G, Xu Y, Gong M, Cao Y and An R (2014) USP28 is a potential prognostic marker for bladder cancer. Tumor Biol 35, 4017-4022   DOI
14 Zhang Y, Hu R, Wu H et al (2012) OTUB1 Overexpression in Mesangial Cells Is a Novel Regulator in the Pathogenesis of Glomerulonephritis through the Decrease of DCN Level. PLoS One 7, e29654   DOI
15 Weng W, Zhang Q, Xu M et al (2016) OTUB1 promotes tumor invasion and predicts a poor prognosis in gastric adenocarcinoma. Am J Transl Res 8, 2234-2244
16 Xu L, Li J, Bao Z et al (2017) Silencing of OTUB1 inhibits migration of human glioma cells in vitro. Neuropathology 37, 217-226   DOI
17 Catrysse L, Vereecke L, Beyaert R and van Loo G (2014) A20 in inflammation and autoimmunity. Trends Immunol 35, 22-31   DOI
18 Ndubaku C and Tsui V (2015) Inhibiting the deubiquitinating enzymes (DUBs). J Med Chem 58, 1581-1595   DOI
19 Liu H, Zhang Q, Li K et al (2016) Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into arrestin-dependent ERK signaling. Oncotarget 7, 81223-81240   DOI
20 Li Y, Li J, Liu H, Liu Y and Cui B (2017) Expression of MYSM1 is associated with tumor progression in colorectal cancer. PLoS One 12, e0177235   DOI
21 Huang Y, Pan XW, Li L et al (2016) Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation. Oncotarget 7, 22016-22030   DOI
22 Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43, 1022-1025   DOI
23 Chiu HW, Lin HY, Tseng IJ, Hsiao M and Lin YF (2018) OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer. Oncotarget 9, 553-565   DOI
24 Arpalahti L, Saukkonen K, Hagstrom J et al (2017) Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma. Tumor Biol 39, 101042831771041
25 Yang H, Zhang C, Fang S, Ou R, Li W and Xu Y (2015) UCH-LI acts as a novel prognostic biomarker in gastric cardiac adenocarcinoma. Int J Clin Exp Pathol 8, 13957-13967
26 Hussain S, Bedekovics T, Chesi M, Bergsagel PL and Galardy PJ (2015) UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression. Oncotarget 6, 40704-40718   DOI
27 Kwon J, Mochida K, Wang YL et al (2005) Ubiquitin C-Terminal Hydrolase L-1 Is Essential for the Early Apoptotic Wave of Germinal Cells and for Sperm Quality Control During Spermatogenesis. Biol Reprod 73, 29-35   DOI
28 Hansen GM, Skapura D and Justice MJ (2000) Genetic profile of insertion mutations in mouse leukemias and lymphomas. Genome Res 10, 237-243   DOI
29 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A (2012) Global cancer statistics. CA Cancer J Clin 65, 87-108
30 Li J, Shen H and Himmel KL (1999) Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet 23, 348-353   DOI
31 Fishel R, Lescoe MK, Rao MR et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75, 1027-1038   DOI
32 Sharma A, Alswillah T, Singh K et al (2018) USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination. Autophagy 14, 1976-1990   DOI
33 Brackeva B, De Punt V, Kramer G et al (2015) Potential of UCHL1 as biomarker for destruction of pancreatic beta cells. J Proteomics 117, 156-167   DOI
34 Liu C, Liu C, Liu H et al (2017) Increased Expression of Ubiquitin-Specific Protease 4 Participates in Neuronal Apoptosis After Intracerebral Hemorrhage in Adult Rats. Cell Mol Neurobiol 37, 427-435   DOI
35 He B, Zhao YC, Gao LC et al (2016) Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Pathological Cardiac Hypertrophy. Hypertension 67, 1237-1248   DOI
36 Oliveira AM and Chou MM (2014) USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis. Hum Pathol 45, 1-11   DOI
37 Lewis SB, Wolper R, Chi YY et al (2010) Identification and preliminary characterization of ubiquitin C terminal hydrolase 1 (UCHL1) as a biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage. J Neurosci Res 88, 1475-1484   DOI
38 Papa L, Akinyi L, Liu MC et al (2010) Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 38, 138-144   DOI
39 Song YL, Yu R, Qiao X-W et al (2017) Prognostic relevance of UCH-L1 and ${\alpha}$-internexin in pancreatic neuroendocrine tumors. Sci Rep 7, 2205   DOI
40 D'Arcy P, Wang X and Linder S (2015) Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther 147, 32-54   DOI
41 Kaushal K, Antao AM, Kim KS and Ramakrishna S (2018) Deubiquitinating enzymes in cancer stem cells: functions and targeted inhibition for cancer therapy. Drug Discov Today 23, 1974-1982   DOI
42 Komander D (2009) The emerging complexity of protein ubiquitination. Biochem Soc Trans 37, 937-953   DOI
43 Love KR, Catic A, Schlieker C and Ploegh HL (2007) Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol 3, 697-705   DOI
44 Brnjic S, Mazurkiewicz M, Fryknas M et al (2014) Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Antioxid Redox Signal 21, 2271-2285   DOI
45 Harrigan JA, Jacq X, Martin NM et al (2017) Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov 17, 57-78   DOI
46 Okada K, Ye YQ, Taniguchi K et al (2013) Vialinin A is a ubiquitin-specific peptidase inhibitor. Bioorg Med Chem Lett 23, 4328-4331   DOI
47 Jacq X, Kemp M, Martin NMB and Jackson SP (2013) Deubiquitylating Enzymes and DNA Damage Response Pathways. Cell Biochem Biophys 67, 25-43   DOI
48 Chandrasekaran AP, Suresh B, Kim HH, Kim K-S and Ramakrishna S (2017) Concise Review: Fate Determination of Stem Cells by Deubiquitinating Enzymes. Stem Cells 35, 9-16   DOI
49 Lork M, Verhelst K and Beyaert R (2017) CYLD, A20 and OTULIN deubiquitinases in NF-${\kappa}B$ signaling and cell death: so similar, yet so different. Cell Death Differ 24, 1172-1183   DOI
50 Darling S, Fielding AB, Sabat-Pospiech D, Prior IA and Coulson JM (2017) Regulation of the cell cycle and centrosome biology by deubiquitylases. Biochem Soc Trans 45, 1125-1136   DOI
51 Nijman SMB, Luna-Vargas MPA and Velds A (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786   DOI
52 Abdul Rehman SA, Kristariyanto YA, Choi SY et al (2016) MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes. Mol Cell 63, 146-155   DOI
53 Priolo C, Tang D, Brahamandan M et al (2006) The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 66, 8625-8632   DOI
54 Qu Q, Mao Y, Xiao G et al (2015) USP2 promotes cell migration and invasion in triple negative breast cancer cell lines. Tumor Biol 36, 5415-5423   DOI
55 Zhang L, Zhou F, Drabsch Y et al (2012) USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-${\beta}$ type i receptor. Nat Cell Biol 14, 717-726   DOI
56 Seibold MA and Schwartz DA (2011) The authors reply. N Engl J Med 364, 1503-1512   DOI
57 Colland F, Formstecher E, Jacq X et al (2009) Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 8, 2286-2295   DOI
58 Yang J, Xu P, Han L et al (2015) Cutting Edge: Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing $ROR{\gamma}t$. J Immunol 194, 4094-4097   DOI
59 Gavory G, O'dowd C, McClelland K et al (2015) Abstract LB-257: Discovery and characterization of novel, highly potent and selective USP7 inhibitors. Cancer Res 75, 15   DOI
60 Reverdy C, Conrath S, Lopez R et al (2012) Discovery of Specific Inhibitors of Human USP7/HAUSP Deubiquitinating Enzyme. Chem Biol 19, 467-477   DOI
61 Weinstock J, Wu J, Cao P et al (2012) Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. ACS Med Chem Lett 3, 789-792   DOI
62 Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M and Donato NJ (2010) Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis. Cancer Res 70, 9265-9276   DOI
63 Burkhart RA, Peng Y, Norris ZA et al (2013) Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival. Mol Cancer Res 11, 901-911   DOI
64 Lee B-H, Lee MJ, Park S et al (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184   DOI
65 Cao WH, Liu XP, Meng SL et al (2016) USP4 promotes invasion of breast cancer cells via Relaxin/TGF-${\beta}$1/Smad2/MMP-9 signal. Eur Rev Med Pharmacol Sci 20, 1115-1122
66 Xing C, Lu XX, Guo P Da et al (2016) Ubiquitin-specific protease 4-mediated deubiquitination and stabilization of PRL-3 is required for potentiating colorectal oncogenesis. Cancer Res 76, 83-95   DOI
67 Guo W, Ma J, Pei T et al (2018) Up-regulated deubiquitinase USP4 plays an oncogenic role in melanoma. J Cell Mol Med 22, 2944-2954   DOI
68 Li T, Yan B, Ma Y et al (2018) Ubiquitin-specific protease 4 promotes hepatocellular carcinoma progression via cyclophilin A stabilization and deubiquitination. Cell Death Dis 9, 148-165   DOI
69 Hicke L (2001) Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2, 195-201   DOI
70 Tang B, Tang F, Li B et al (2015) High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget 6, 12654-12667   DOI
71 Liu Y, Wang W, Lu Y et al (2017) Usp5 functions as an oncogene for stimulating tumorigenesis in hepatocellular carcinoma 8, 50655-50664   DOI
72 Li XY, Wu HY, Mao XF, Jiang LX and Wang YX (2017) USP5 promotes tumorigenesis and progression of pancreatic cancer by stabilizing FoxM1 protein. Biochem Biophys Res Commun 492, 48-54   DOI
73 Cheon KW and Baek KH (2006) HAUSP as a therapeutic target for hematopoietic tumors (Review). Int J Oncol 28, 1209-1215
74 Zhang L, Wang H, Tian L and Li H (2016) Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer. Tohoku J Exp Med 239, 165-175   DOI
75 Gu Y, Ding X, Huang J et al (2018) The deubiquitinating enzyme UCHL1 negatively regulates the immunosuppressive capacity and survival of multipotent mesenchymal stromal cells. Cell Death Dis 9, 459   DOI
76 Deng H, O'Keefe H, Davie CP et al (2012) Discovery of Highly Potent and Selective Small Molecule ADAMTS-5 Inhibitors That Inhibit Human Cartilage Degradation via Encoded Library Technology (ELT). J Med Chem 55, 7061-7079   DOI
77 Yue W, Chen Z, Liu H et al (2014) A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30. Cell Res 24, 482-496   DOI
78 Tian Z, D'Arcy P, Wang X et al (2014) A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123, 706-716   DOI
79 Lei H, Shan H and Wu Y (2017) Targeting deubiquitinating enzymes in cancer stem cells. Cancer Cell Int 17, 101   DOI
80 D'Arcy P, Wang X and Linder S (2015) Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther 147, 32-54   DOI
81 Zou Y, Qiu G, Jiang L et al (2017) Overexpression of ubiquitin specific proteases 44 promotes the malignancy of glioma by stabilizing tumor-promoter securin. Oncotarget 8, 58231-58246   DOI
82 Boustani MR, Khoshnood RJ, Nikpasand F et al (2016) Overexpression of ubiquitin-specific protease 2a (USP2a) and nuclear factor erythroid 2-related factor 2 (Nrf2) in human gliomas. J Neurol Sci 363, 249-252   DOI
83 Liu R, Zhao D, Zhang X et al (2017) A20 enhances the radiosensitivity of hepatocellular carcinoma cells to 60Co-$\gamma$ ionizing radiation. Oncotarget 8, 93103-93116   DOI
84 Zhang QX, Wang XC, Chen SP and Qin XT (2016) Predictive value of deubiquitination enzymes USP37 in the prognosis of breast cancer. Zhonghua Yi Xue Za Zhi 96, 944-948
85 Qu Q, Mao Y, Xiao G et al (2015) USP2 promotes cell migration and invasion in triple negative breast cancer cell lines. Tumor Biol 36, 5415-5423   DOI
86 Ni Q, Chen J, Li X et al (2017) Expression of OTUB1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion. Acta Biochim Biophys Sin (Shanghai) 49, 680-688   DOI
87 Yao R, Pu J, Fan R et al (2017) Ubiquitin-specific protease 4 improves the prognosis of the patients in esophageal cancer. Cancer Biomarkers 20, 317-323   DOI
88 Baykara M, Yaman M, Buyukberber S et al (2009) Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer. J BUON 18, 921-927
89 Fraile JM, Quesada V, Rodriguez D, Freije JMP and Lopez-Otin C (2012) Deubiquitinases in cancer: New functions and therapeutic options. Oncogene 31, 2373-2388   DOI
90 Zhang C, Lu J, Zhang Q-W et al (2016) USP7 promotes cell proliferation through the stabilization of Ki-67 protein in non-small cell lung cancer cells. Int J Biochem Cell Biol 79, 209-221   DOI
91 Xia R, Jia H, Fan J, Liu Y and Jia J (2012) USP8 promotes smoothened signaling by preventing its ubiquitination and changing its subcellular localization. PLoS Biol 10, e1001238   DOI
92 Mukai A, Yamamoto-Hino M, Awano W, Watanabe W, Komada M and Goto S (2010) Balanced ubiquitylation and deubiquitylation of Frizzled regulate cellular responsiveness to Wg/Wnt. EMBO J 29, 2114-2225   DOI
93 Yan M, Zhao C, Wei N, Wu X, Cui J and Xing Y (2018) High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma. Med Sci Monit 24, 4934-4943   DOI
94 Soncini C, Berdo I and Draetta G (2001) Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10. Oncogene 20, 3869-3879   DOI
95 Piao S, Ma J, Wang W et al (2013) Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncol 49, 796-801   DOI
96 Zhang B, Wang H, Yang L et al (2016) OTUD7B and NIK expression in non-small cell lung cancer: Association with clinicopathological features and prognostic implications. Pathol Res Pract 212, 893-898   DOI
97 Li J, Wang Z and Li Y (2012) USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 138, 1291-1297   DOI
98 Wang X, Zhang Q, Wang Y, Zhuang H and Chen B (2018) Clinical Significance of Ubiquitin Specific Protease 7 (USP7) in Predicting Prognosis of Hepatocellular Carcinoma and its Functional Mechanisms. Med Sci Monit 24, 1742-1750   DOI
99 Kim Y, Shiba-Ishii A, Nakagawa T et al (2017) Ubiquitinspecific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma. Pathol Int 67, 292-301   DOI
100 Zeng Z, Wu HX, Zhan N et al (2014) Prognostic significance of USP10 as a tumor-associated marker in gastric carcinoma. Tumor Biol 35, 3845-3853   DOI